REGENXBIO to Present Pre-Clinical Data

REGENXBIO said it will present pre-clinical data supporting further clinical research regarding the use of its investigational gene therapy RGX-314 for the treatment of wet age-related macular degeneration.

“RGX-314 has the potential to be a one-time treatment for people with wet AMD by delivering high expression of anti-VEGF antibodies through the use of our NAV AAV8 vector. We are pleased to share additional positive preclinical results, which were generated by our development partners at the University of Pennsylvania and Johns Hopkins, which support our active IND,” said CEO Kenneth Mills. “REGENXBIO is on track to begin enrollment in the RGX-314 phase I clinical trial by mid-2017 and to provide an interim trial update by the end of 2017.”

Leave a Comment